Opendata, web and dolomites

BMPARK SIGNED

Development of BMP2 Neurotrophic Therapy for Parkinson’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BMPARK project word cloud

Explore the words cloud of the BMPARK project. It provides you a very rough idea of what is the project "BMPARK" about.

inclusions    total    viral    nigra    contribution    neurotrophic    synuclein    century    relevance    bmp    neuroprotective    people    molecular    vectors    economy    protect    independence    neurons    signalling    intraneuronal    despite    highlight    progressive    transgene    hallmarks    substantia    brain    rat    context    motor    demographic    transformative    billion    trials    protein    levels    individuals    extensive    neurite    career    maturity    mechanism    axons    double    bmp2    therapy    paralleled    societal    bodies    alpha    annum    million    midbrain    projected    worldwide    stakeholders    scientific    socioeconomic    pd    plans    therapies    lewy    dopaminergic    region    function    dopamine    neurodegenerative    accumulation    predominantly    me    2030    half    clinical    parkinson    training    multidisciplinary    professional    disease    neuropathological    consist    model    aging    degeneration    intensive    communication    bone    morphogenetic    investigation    modifying    direct    13    date    efficacy   

Project "BMPARK" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK 

Organization address
address: WESTERN ROAD
city: Cork
postcode: T12 YN60
website: www.ucc.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 184˙590 €
 EC max contribution 184˙590 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK IE (Cork) coordinator 184˙590.00

Map

 Project objective

Parkinson’s Disease (PD) is a progressive neurodegenerative disease. PD affects more than 6 million people worldwide while 1.2 million people have PD in Europe. For the European economy PD has a total socioeconomic cost of €13.9 billion per annum. With the aging demographic the number of individuals affects by PD are projected to double by 2030 highlight the need for disease modifying therapies. The neuropathological hallmarks of PD are the progressive loss of dopaminergic neurons in a region of the brain known as the substantia nigra in the midbrain, and the accumulation of intraneuronal inclusions called Lewy bodies and lewy neurite that consist predominantly of a protein called α-synuclein. Despite over half a century of investigation, there is no disease modifying therapy for PD. I propose that a protein called bone morphogenetic protein (BMP)2 can protect midbrain dopaminergic neurons in the PD brain. BMP2 is distinct from other neurotrophic factors used in the clinical trials to date in that it has a different signalling mechanism that can be targeted to protect dopaminergic neurons. Here I will assess the neuroprotective efficacy of viral vectors carrying the BMP2 transgene in the rat α-synuclein model of PD. I will determine if this molecular therapy can protect dopamine neurons and their axons against α-synuclein induced degeneration to maintain brain dopamine levels and improve motor function. To do this, I will use a multidisciplinary approach which will be paralleled by intensive training and career development opportunities to enable me to make a transformative contribution to knowledge and to achieve professional maturity and independence. In this way, this work has direct relevance for the future development of neurotrophic factors for clinical use in PD and the extensive dissemination and communication plans to target all stakeholders will ensure both societal and scientific impact in an European context and also for individuals with PD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BMPARK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BMPARK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Widow Spider Mating (2020)

Immature mating as a novel tactic of an invasive widow spider

Read More  

STOPATT (2020)

Stochastic pattern formation in biochemical systems

Read More  

Inflapoptosis (2019)

Gasdermin D is a novel effector in the extrinsic apoptosis pathway

Read More